Gavis and Lupin sell rights to generic drugs

Lupin and Gavis Pharmaceuticals have agreed to divest from two generic drugs as part of their agreement with the Federal Trade Commission. After Lupin acquired Gavis for $880 million last year, the FTC came to the conclusion that Lupin needed to sell the rights to a generic that treated bacterial infections and another that treated ulcerative colitis for competitive reasons. The generics were sold to G&W Laboratories.

Read the source article at DNA India